Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Warning Sign:
Beneish M-Score 1.59 higher than -1.78, which implies that the company might have manipulated its financial results.
The historical rank and industry rank for Blue Jet Healthcare's Beneish M-Score or its related term are showing as below:
BOM:544009'
s Beneish M-Score Range Over the Past 10 Years
Min: -1.03 Med: -0.59 Max: 1.59
Current: 1.59
During the past 6 years, the highest Beneish M-Score of Blue Jet Healthcare was 1.59. The lowest was -1.03. And the median was -0.59.
Blue Jet Healthcare Beneish M-Score Related Terms
Blue Jet Healthcare Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Blue Jet Healthcare's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544009 vs VRTX, REGN, ALNY: Beneish M-Score Comparison
For the Biotechnology subindustry, Blue Jet Healthcare's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blue Jet Healthcare Beneish M-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Blue Jet Healthcare's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Blue Jet Healthcare's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Blue Jet Healthcare for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.0425
+
0.528 * 1.0227
+
0.404 * 9.2221
+
0.892 * 0.9197
+
0.115 * 1.1208
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 1
+
4.679 * 0.151001
-
0.327 * 0.8403
=
1.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(177.89 / (177.89 + 4051.7))
/
(240.02 / (240.02 + 6156.29))
=
0.042058
/
0.037525
=
1.1208
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(2478.16 - 0
-
0)
/
16411.58
=
0.151001
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Blue Jet Healthcare has a M-score of 1.59 signals that the company is likely to be a manipulator.
Blue Jet Healthcare (BOM:544009) has a Beneish M-Score of 1.59 as of Jul. 20, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Blue Jet Healthcare and its competitors. According to the industry distribution chart, Blue Jet Healthcare ranks #729 out of 825 companies in the Biotechnology industry, placing it in the top 88.4%.
Is Blue Jet Healthcare's Beneish M-Score too high?
Blue Jet Healthcare's current Beneish M-Score is 1.59. Based on the distribution chart, Blue Jet Healthcare ranks #729 out of 825 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Blue Jet Healthcare has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Blue Jet Healthcare's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Blue Jet Healthcare ranks #729 out of 825 companies for Beneish M-Score. This places Blue Jet Healthcare in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Blue Jet Healthcare and its competitors. Blue Jet Healthcare's current Beneish M-Score is 1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blue Jet Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Blue Jet Healthcare (BOM:544009) is currently considered Fairly Valued. The stock's GF Value™ is ₹562.05, compared to a current price of ₹589.75 — trading 4.9% above its estimated fair value. The current Beneish M-Score is 1.59. Blue Jet Healthcare's overall GF Score™ is 64/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Blue Jet Healthcare (BOM:544009), the current Beneish M-Score is 1.59 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blue Jet Healthcare (BOM:544009) Overvalued in 2026?
Based on GuruFocus' analysis, Blue Jet Healthcare stock appears to be overvalued.
The current stock price of ₹589.75 is trading 4.9% above its estimated GF Value™ of ₹562.05.
GuruFocus considers Blue Jet Healthcare to be Fairly Valued.
Key valuation signals for BOM:544009:
Beneish M-Score: 1.59
GF Value™: ₹562.05 vs. price of ₹589.75 (4.9% above fair value)
No single metric tells the full story. See the BOM:544009 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blue Jet Healthcare Ltd is engaged in manufacturing of Pharma Intermediate, APIs used in Pharmaceutical and Healthcare Products. The operations of the company are organized in three product categories which are contrast media intermediates, artificial sweeteners, pharma intermediates, and active pharmaceutical ingredients. Geographically, it operates in Norway, France, India and Rest of the World.
64GF Score
Get the complete analysis for BOM:544009
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544009 has been successfully added to your 
